A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4+ T lymphocytes

International Immunology

Volumn 12, Issue 3, 2000, Pages 281-293

  Rajnavölgyi, Éva ^a,b   Nagy, Noémi ^a   Thuresson, Britt ^c   Dosztányi, Zsuzsa ^d   Simon, Ágnes ^d   Simon, István ^d   Karr, Robert W ^e   Ernberg, Ingemar ^a   Klein, Eva ^a   Falk, Kerstin I ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d INSTITUTE OF ENZYMOLOGY   (Hungary)

^e PFIZER INC   (United States)

Author keywords

HLA DR peptide interaction; Human CD4+ T lymphocyte; Virus specific immunity

Indexed keywords

CD4 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2; SYNTHETIC PEPTIDE; T LYMPHOCYTE ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BIOASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 12944316539     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/12.3.281     Document Type: Article

References (63)

1. Henle, G. and Henle, W. 1979. The virus as the etiological agent of infectious mononucleosis. In Epstein, M. A. and Achong, B. G., eds. The Epstein-Barr Virus. p. 297. Springer, Berlin.
2. Klein, G. 1991. Immunovirology of transforming viruses. Curr. Opin. Immunol. 3:665.
3. Khanna, R., Burrows, S. R. and Moss, D. J. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387.
4. Masucci, M. G. and Ernberg, I. 1994. Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol. 2:125.
5. Falk, K., Linde, A., Johnson, D., Lennette, E., Ernberg, I. and Lundkvist, A. 1995. Synthetic peptides deduced from the amino acid sequence of Epstein-Barr virus nuclear antigen 6 (EBNA 6): antigenic properties, production of monoreactive reagents, and analysis of antibody responses in man. J. Med. Virol. 46:349.
6. Klein, G. 1994. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 77:791.
7. Rickinson, A. B., Lee, S. P. and Steven, N. M. 1996. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr. Opin. Immunol. 8:492.
8. Rickinson, A. B. and Moss, D. J. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405.
9. Klein, E. 1998. The complexity of the Epstein-Barr virus infection in humans. Pathol. Oncol. Res. 4:3.
10. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187:1395.
11. + T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1827.
12. Thomas, J. A., Allday, M. J. and Crawford, D. H. 1991. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv. Cancer Res. 57:329.
13. Lau, L. L., Jamieson, B. D., Somasundaram, T. and Ahmed, R. 1994. Cytotoxic T cell memory without antigen. Nature 369:648.
14. Bachmann, M. F., Kundig, T. M., Hengartner, H. and Zinkernagel, R. M. 1997. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without 'memory T cells'? Proc. Natl Acad. Sci. USA 94:640.
15. + T cells. J. Exp. Med. 184:863.
16. + T cells. Curr. Opin. Immunol. 10:444.
17. Khanna, R., Burrows, S. R., Steigerwald-Mullen, P. M., Moss, D. J., Kurilla, M. G. and Cooper, L. 1997. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int. Immunol. 9:1537.
18. + EBV-specific CTLs. J. Immunol. 158:3619.
19. Dillner, J. and Kallin, B. 1988. The Epstein-Barr virus proteins. Adv. Cancer Res. 50:95.
20. Chen, F., Zou, J. Z., di Renzo, L., Winberg, G., Hu, L. F., Klein, E., Klein, G. and Ernberg, I. 1995. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol. 69:3752.
21. Sharipo, A., Imreh, M., Leonchiks, A., Imreh, S. and Masucci, M. G. 1998. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 4:939.
22. Hennessy, K. and Kieff, E. 1985 A second nuclear protein is encoded by Epstein-Barr virus in latent infection. Science 227:1238.
23. Farrell, P. J. 1989. Epstein-Barr virus genome. In Klein, G., ed., Advances in Viral Oncology, vol. 8, p. 103. Raven Press, New York.
24. Linde, A., Kallin, B., Dillner, J., Andersson, J., Jagdahl, L., Lindvall, A. and Wahren, B. 1990. Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J. Infect. Dis. 161:903.
25. Lennette, E. T., Rymo, L., Yadav, M., Masucci, G., Merk, K., Timar, L. and Klein, G. 1993. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur. J. Cancer 29A:1584.
26. d)-restricted T cell recognition of influenza hemagglutinin: B cell epitopes define T cell epitopes. Eur. J. Immunol. 19:523.
27. Scherle, P. A. and Gerhard, W. 1988. Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T cell clones in vivo. Proc. Natl Acad. Sci. USA 85:4446.
28. Rajnavolgyi, E., Horvath, A., Gogolak, P., Toth, G. K., Fazekas, G., Fridkin, M. and Pecht, I. 1997. Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites. Eur. J. Immunol. 27:3105.
29. Ray, J. G., Hare, D. B., Pedersen, P. D. and Mullally, D. I. 1976. NIAD Manual of Tissue Typing Techniques, p. 22. DHEW, Bethesda MD.
30. Olerup, O. and Zetterquist, H. 1992. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39:225.
31. Vidovic, D., Falcioni, F., Siklodi, B., Belunis, C. J., Bolin, D. R., Ito, K. and Nagy, Z. 1995. Downregulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragments. Eur. J. Immunol. 25:3349.
32. Woods, A., Chen, H. Y., Trumbauer, M. E., Sirotina, A., Cummings, R. and Zaller, D. M. 1994. Human major histocompatibility complex class II-restricted T cell responses in transgenic mice. J. Exp. Med. 180:173.
33. Kovats, S., Drover, S., Marshall, W. H., Freed, D., Whiteley, P. E., Nepom, G. T. and Blum, J. S. 1994. Coordinate defects in human histocompatibility leukocyte antigen class II expression and antigen presentation in bare lymphocyte syndrome. J. Exp. Med. 179:2017.
34. Tieber, V. L., Abruzzini, L. F., Didier, D. K., Schwartz, B. D. and Rotwein, P. 1986. Complete characterization and sequence of an HLA class II DR beta chain cDNA from the DR5 haplotype. J. Biol. Chem. 261:2738.
35. Lenoir, G. M., Vuillaume, M. and Bonnardel, D. 1985. The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma. In Burkitt's Lymphoma: A Human Cancer Model, vol. 60, p. 309. IARC Scientific Publications, Lyon.
36. Wang, F., Gregory, C., Sample, C., Rowe, M., Liebowitz, D., Murray, R., Rickinson, A. and Kieff, E. 1990. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64:2309.
37. Espevik, T. and Nissen-Meyer, J. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 95:99.
38. Mozes, E., Dayan, M., Zisman, E., Brocke, S., Licht, A. and Pecht, I. 1989. Direct binding of a myasthenia gravis related epitope to MHC class II molecules on living murine antigen-presenting cells. EMBO J. 8:4049.
39. Stern, L. J., Brown, J. H., Jardetzky, T. S., Gorga, J. C., Urban, R. G., Strominger, J. L. and Wiley, D. C. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215.
40. Dessen, A., Lawrence, C. M., Cupo, S., Zaller, D. M. and Wiley, D. C. 1997. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7:473.
41. Connolly, M. L. 1983. Solvent-accessible surfaces of proteins and nucleic acids. Science 221:709.
42. Rammensee, H. G., Friede, T. and Stevanovic, S. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
43. Hammer, J., Gallazzi, F., Bono, E., Karr, R. W., Guenot, J., Valsasnini, P., Nagy, Z. A. and Sinigaglia, F. 1995. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J. Exp. Med. 181:1847.
44. Rotzschke, O. and Falk, K. 1994. Origin, structure and motifs of naturally processed MHC class II ligands. Curr. Opin. Immunol. 6:45.
45. Chicz, R. M., Urban, R. G., Gorga, J. C., Vignali, D. A., Lane, W. S. and Strominger, J. L. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27.
46. Southwood, S., Sidney, J, Kondo, A., del Guercio, M. F., Appella, E. Hoffman, S., Kubo, R. T., Chesnut, R. W., Grey, H. M. and Sette, A. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160:3363.
47. Murthy, V. L. and Stern, L. J. 1997. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding. Structure 5:1385.
48. Sette, A. and Sidney, J. 1998. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr. Opin. Immunol. 10:478.
49. Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G. and Lanzavecchia, A. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237.
50. Rotzschke, O., Falk, K. and Strominger, J. L. 1997. Superactivation of an immune response triggered by oligomerized T cell epitopes. Proc. Natl Acad. Sci. USA 94:14642.
51. Falk, K., Gratama, J. W., Rowe, M., Zou, J. Z., Khanim, F., Young, L. S., Oosterveer, M. A. and Ernberg, I. 1995. The role of repetitive DNA sequences in the size variation of Epstein-Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis. J. Gen. Virol. 76:779.
52. Croft, M. and Dubey, C. 1997. Accessory molecule and costimulation requirements for CD4 T cell response. Crit. Rev. Immunol. 17:89.
53. Holmgren, L., Szeles, A., Rajnavölgyi, E., Folkman, J., Klein, G., Ernberg, I. and Falk, K. I. 1999. Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood 93:3956.
54. Albert, M. L., Sauter, B. and Bhardwaj, N. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.
55. Lechler, R., Aichinger, G. and Lightstone, L. 1996. The endogenous pathway of MHC class II antigen presentation. Immunol. Rev. 151:51.
56. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7:791.
57. Abbas, A. K., Murphy, K. M. and Sher, A. 1996. Functional diversity of helper T lymphocytes. Nature 383:787.
58. Andersson, J., Abrams, J., Bjork, L., Funa, K., Litton, M., Agren, K. and Andersson, U. 1994. Concomitant in vivo production of 19 different cytokines in human tonsils. Immunology 83:16.
59. Sayos, J., Wu, C., Morra, M., Wang, N., Zhang, X., Allen, D., van Schaik, S., Notarangelo, L., Geha, R., Roncarolo, M. G., Oettgen, H., De Vries, J. E., Aversa, G. and Terhorst, C. 1998. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395:462.
60. Aversa, G., Chang, C. C., Carballido, J. M., Cocks, B. G. and de Vries, J. E. 1997. Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production. J. Immunol. 158:4036.
61. + T-helper and a T-killer cell. Nature 393:474
62. Levitsky, V., de Campos-Lima, P. O., Frisan, T. and Masucci, M. G. 1998. The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J. Immunol. 161:594.
63. + T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis. Int. Immunol. 10:1149.